RE: 'due diligence'6 Oct 2022 14:54
As investors in this stock we are still in two camps.
Those that fully believe that SA is likely to produce a much better deal which caused him to turn down 1.2M income, and those that are sceptical that this is the truth and that its in essence a failed product launch backed by excuses.
Shareprice is languishing at a depressed 15-16p, however not surprising because we currently have poor income.
If you are in the former camp this represents a stunning buying opportunity.
Any decent uplift with news could easily see a return to previous levels.
I myself also want to believe the former, but suspect the later will prove to be the case. I base my judgement on a few facts we can actually prove, albeit with a little leeway.
"Pre-registrations rising at an alarming rate" (SA ), well I knew of 5 that pre-registered, and they all subsequently purchased, so when I heard that number was many thousands indeed 10's of thousands.. I did share that info here, and probably rightly so got a proper reaming when it just wasn't correct by a bit but a country mile.
Well I know I didn't make that figure up, and also witnessed SA saying the statement about "an alarming rate". So something smells badly amiss, and indeed sales proved to be a huge miss despite having stock available.
Next we have the UK psoriasis association. Heard that they wont indorse as its not passed clinic tests...Well we understand why we didn't go down that road, however it seems its a major sticking point and I know its led to heated viewpoints on other UK psoriasis forums .
Lastly we have USA sales and the mighty NPF. I actually believed once our influencers got rolling and the campaign started (hopefully being endorsed by the NPF) sales would flood in. However this is USA where money talks.. and other companies probably use different lines of influence and spend multi dollars on their advertising. Clearly the previously "highly local NPF ", ..remember who told us this????, have gone as quiet as a church mouse, now the product is available for purchase.
However our company does have a few other highly significant strings to its bow, although I'd love to hear what the Croda/Sederma client feedback is right now. So I do believe the current share price is a very good buy, but why I'm still in the former camp, but hope to be proved wrong.